347 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
4
Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives.
Takeda Pharmaceutical
75
Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Instituto De Qu£Mica M£Dica (Iqm-Csic)
7
Synthesis of new derivatives of 21-imidazolyl-16-dehydropregnenolone as inhibitors of 5a-reductase 2 and with cytotoxic activity in cancer cells.
Universidad Nacional Aut£Noma De M£Xico
12
[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.
Bristol Myers Squibb
37
Discovery of indazole ethers as novel, potent, non-steroidal glucocorticoid receptor modulators.
AstraZeneca
16
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Integral Biosciences
33
Development of 6-arylcoumarins as nonsteroidal progesterone antagonists. Structure-activity relationships and fluorescence properties.
Ochanomizu University
4
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
Cardiff University
51
Optimizing Ligand Efficiency of Selective Androgen Receptor Modulators (SARMs).
Glaxosmithkline
3
7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
Cardiff University
5
2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile: A Transdermal Selective Androgen Receptor Modulator (SARM) for Muscle Atrophy.
Eli Lilly
18
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
AstraZeneca
18
Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
Ochanomizu University
15
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Bristol Myers Squibb
5
Discovery of Potent 17ß-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.
University of Arizona
16
Indole Glucocorticoid Receptor Antagonists Active in a Model of Dyslipidemia Act via a Unique Association with an Agonist Binding Site.
Eli Lilly
20
Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
Alla Chem
19
Synthesis and Biological Evaluation of Cyclopentaquinoline Derivatives as Nonsteroidal Glucocorticoid Receptor Antagonists.
TBA
39
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Seragon Pharmaceuticals
33
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.
Merck Research Laboratories
25
2-Aryl-3-methyloctahydrophenanthrene-2,3,7-triols as potent dissociated glucocorticoid receptor agonists.
TBA
12
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
University of Maryland
10
Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.
University of Gothenburg
16
Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I.
Takeda Pharmaceutical
14
3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration.
Novartis Institutes For Biomedical Research
18
Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).
University of British Columbia
24
Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.
Bristol Myers Squibb
2
Synthetic derivatives of aromatic abietane diterpenoids and their biological activities.
Universidad De Valencia
20
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.
Phenex Pharmaceuticals
29
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Takeda Pharmaceutical
45
The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.
AstraZeneca
23
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
Pfizer
3
Preliminary investigations into triazole derived androgen receptor antagonists.
Deakin University
22
Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
Merck Research Laboratories
27
1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators.
Pfizer
12
Glucocorticoid receptor modulators informed by crystallography lead to a new rationale for receptor selectivity, function, and implications for structure-based design.
Eli Lilly
17
Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.
Pfizer
19
Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists.
Tokyo Medical and Dental University
2
Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.
National Cancer Institute-Frederick
42
Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists.
Ironwood Pharmaceuticals
21
Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists.
Bristol Myers Squibb
15
Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists.
Takeda Pharmaceutical
77
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
Merck Research Laboratories
6
Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERa-selective antagonist.
The University of Tokyo
6
Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
Korea Research Institute of Chemical Technology
10
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
University of Maryland
14
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Broad Institute of Mit and Harvard
17
The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity.
Meijo University
1
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AstraZeneca
4
SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer.
Chonnam National University
17
Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange.
The University of Tokyo
17
Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.
Takeda Pharmaceutical
61
Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17ß-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Vanderbilt University School of Medicine
55
Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.
University of British Columbia
4
"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.
Trinity College
11
Discovery of quinolines as selective glucocorticoid receptor agonists.
Bayer Schering Pharma
38
Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists.
Glaxosmithkline
18
Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.
Acadia Pharmaceuticals
14
2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists.
Glaxosmithkline
1
The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist.
Glaxosmithkline
116
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
University of Basel
2
Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
Schering
1
Discovery of diarylhydantoins as new selective androgen receptor modulators.
Galapagos, Parc Biocitech
10
Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
Pfizer
32
Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[d]isoxazole-containing androgen receptor modulators.
University of Eastern Finland
4
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.
Perelman School of Medicine University of Pennsylvania
13
Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.
Pfizer
1
Methoxychalcone inhibitors of androgen receptor translocation and function.
National Cancer Institute-Bethesda
22
Dimethyl-diphenyl-propanamide Derivatives As Nonsteroidal Dissociated Glucocorticoid Receptor Agonists.
Bristol Myers Squibb
10
Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.
Chugai Pharmaceutical
22
Synthesis of potent, substituted carbazoles as selective androgen receptor modulators (SARMs).
Radius Health
22
Novel selective anti-androgens with a diphenylpentane skeleton.
The University of Tokyo
69
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
Pfizer
47
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
Pfizer
20
1-Methyl-1H-pyrrole-2-carbonitrile containing tetrahydronaphthalene derivatives as non-steroidal progesterone receptor antagonists.
Pfizer
30
Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.
Bristol Myers Squibb
49
Aromatic beta-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists.
Chinese Academy of Sciences
19
Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists.
Chugai Pharmaceutical
3
Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget.
University of Illinois
11
The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144.
Wyeth Research
34
Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: application to the synthesis of glucocorticoid receptor modulators.
Bristol Myers Squibb
24
Discovery of novel dihydro-9,10-ethano-anthracene carboxamides as glucocorticoid receptor modulators.
Bristol Myers Squibb
28
1,5-Dihydro-benzo[e][1,4]oxazepin-2(1H)-ones containing a 7-(5'-cyanopyrrol-2-yl) group as nonsteroidal progesterone receptor modulators.
Wyeth Research
39
7-aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists.
Wyeth Research
25
Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.
Ligand Pharmaceuticals
17
Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4-tetrahydroquinolines.
Ligand Pharmaceuticals
1
Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.
Ligand Pharmaceuticals
1
A surface on the androgen receptor that allosterically regulates coactivator binding.
University of California
4
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
The Scripps Research Institute
31
Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
Wyeth Research
23
Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.
Ligand Pharmaceuticals
31
Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.
Bristol Myers Squibb
17
Bridged androstenediol analogs as ER-beta selective SERMs.
Merck Research Laboratories
31
Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships.
Chugai Pharmaceutical
31
A bioisosteric approach to the discovery of indole carbinol androgen receptor ligands.
Johnson and Johnson Pharmaceutical Research and Development
26
Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands.
Johnson & Johnson Pharmaceutical Research and Development
2
Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.
University of Perugia
6
Binding thermodynamics as a tool to investigate the mechanisms of drug-receptor interactions: thermodynamics of cytoplasmic steroid/nuclear receptors in comparison with membrane receptors.
University of Ferrara
9
11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor.
The Pennsylvania State University
22
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.
Abbott Laboratories
16
Synthesis and structure-activity investigation of iodinated arylhydantoins and arylthiohydantoins for development as androgen receptor radioligands.
The University of Michigan Medical School
10
Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate.
University of Colorado
14
6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists.
Women'S Health Research Institute
9
Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists.
Pfizer
17
Chiral derivatives of 2-cyclohexylideneperhydro-4,7-methanoindenes, a novel class of nonsteroidal androgen receptor ligand: synthesis, X-ray analysis, and biological activity.
The University of Sydney
5
Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand.
The University of Michigan Medical School
25
5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.
Ligand Pharmaceuticals
3
Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071).
Ligand Pharmaceuticals
37
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
Ligand Pharmaceuticals
32
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
Ligand Pharmaceuticals
34
Synthesis and in vitro activity of 17 beta-(N-alkyl/arylformamido)- and 17 beta-[(N-alkyl/aryl)alkyl/arylamido]-4-methyl-4-aza-3-oxo-5 alpha-androstan-3-ones as inhibitors of human 5 alpha-reductases and antagonists of the androgen receptor.
Chul Research Center
9
Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles.
Sterling Winthrop Pharmaceuticals Research Division
131
Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding.
TBA
44
Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists.
Abbott Laboratories
48
Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.
Wyeth Research
26
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
Ligand Pharmaceuticals
17
Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.
Ligand Pharmaceuticals
15
Synthesis and structure-activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands.
The University of Michigan Medical School
22
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
Ligand Pharmaceuticals
24
4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.
Ligand Pharmaceuticals
29
5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
Ligand Pharmaceuticals
23
Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.
Takeda Pharmaceutical
13
Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.
Pfizer
25
Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
Takeda Pharmaceutical
34
Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
Takeda Pharmaceutical
12
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
University of British Columbia
21
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.
Pfizer
22
Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.
Kaken Pharmaceutical
40
Azaxanthene based selective glucocorticoid receptor modulators: design, synthesis, and pharmacological evaluation of (S)-4-(5-(1-((1,3,4-thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and its methylene homologue (BMS-791
Bristol Myers Squibb
32
6-arylcoumarins as novel nonsteroidal type progesterone antagonists: an example with receptor-binding-dependent fluorescence.
Ochanomizu University
40
Pantolactams as androgen receptor antagonists for the topical suppression of sebum production.
Pfizer
6
Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening.
University of British Columbia
3
Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.
The University of Tennessee
17
Nonsteroidal 2,3-dihydroquinoline glucocorticoid receptor agonists with reduced PEPCK activation.
Ligand Pharmaceuticals
6
Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).
Kaken Pharmaceutical
26
Discovery of orally available tetrahydroquinoline-based glucocorticoid receptor agonists.
Ligand Pharmaceuticals
4
Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140
TBA
12
Tetrahydroquinoline glucocorticoid receptor agonists: discovery of a 3-hydroxyl for improving receptor selectivity.
Ligand Pharmaceuticals
6
20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
UniversitäT Leipzig
1
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
30
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Phenex Pharmaceuticals
5
Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery.
Pfizer
13
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
Pfizer
5
Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay.
Meijo University
10
LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators.
The University of Tokyo
36
Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
Sumitomo Chemical
14
Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists.
Glaxosmithkline
20
Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.
Glaxosmithkline
18
Design, synthesis, and biological evaluation of 16-substituted 4-azasteroids as tissue-selective androgen receptor modulators (SARMs).
Merck Research Laboratories
11
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
Meijo University
16
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.
Gtx
30
Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production.
Pfizer
18
Octahydrophenanthrene-2,7-diol analogues as dissociated glucocorticoid receptor agonists: discovery and lead exploration.
Pfizer
34
4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production.
Pfizer
2
Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring.
Tohoku Pharmaceutical University
40
4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor.
The University of Tokyo
7
A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
Ligand Pharmaceuticals
48
Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity.
Guangdong Pharmaceutical University
2
Rational Design of Dual Degraders by Incorporating Molecular Glue Structural Features into PROTAC Degraders.
Ocean University of China
10
Recent advances from computer-aided drug design to artificial intelligence drug design.
China Pharmaceutical University
22
Discovery of N-(1,2,4-Thiadiazol-5-yl)benzo[b]oxepine-4-carboxamide Derivatives as Novel Antiresistance Androgen Receptor Antagonists.
Zhejiang University
16
Discovery of 5-Nitro-N-(3-(trifluoromethyl)phenyl) Pyridin-2-amine as a Novel Pure Androgen Receptor Antagonist against Antiandrogen Resistance.
Zhejiang University
43
Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate Cancer.
Zhejiang University
47
Discovery of Thiadiazoleamide Derivatives as Potent, Selective, and Orally Available Antagonists Disrupting Androgen Receptor Homodimer.
Zhejiang University
15
Discovery of novel spirocyclic derivates as potent androgen receptor antagonists.
China Pharmaceutical University
53
Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease.
Guangdong Pharmaceutical University
28
Discovery of Novel Bifunctional Agents as Potent Androgen Receptor Antagonists and Degraders for the Treatment of Enzalutamide-Resistant Prostate Cancer.
China Pharmaceutical University
8
Small molecule agents against alopecia: Potential targets and related pathways.
Hangzhou Normal University
2
Recent advance of small-molecule drugs for clinical treatment of osteoporosis: A review.
Zhengzhou Normal University
1
Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer.
China Pharmaceutical University
31
Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 Release.
The Scripps Research Institute
6
(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
Eli Lilly
20
Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia.
Insilico Medicine Shanghai Ltd
50
Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
China Pharmaceutical University
14
Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer.
Zhejiang Normal University
3
(1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production.
Pfizer
1
Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression.
University of Kentucky
17
Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists.
Chugai Pharmaceutical
12
Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production.
Pfizer
18
Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production.
Pfizer
30
Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.
Ligand Pharmaceuticals
11
5-(3-Cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile: A novel, highly potent, selective, and orally active non-steroidal progesterone receptor agonist.
Wyeth Research
18
Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
Yantai University
7
Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer.
Zhengzhou Normal University
13
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.
Bristol Myers Squibb
33
5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators.
Ligand Pharmaceuticals
56
Synthesis and Evaluation of Small Molecule Inhibitors of the Androgen Receptor N-Terminal Domain.
University of Strathclyde
24
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
University of Michigan
1
A-ring-fused pyrazoles of dihydrotestosterone targeting prostate cancer cells via the downregulation of the androgen receptor.
Palacky University
43
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.
Guangdong Pharmaceutical University
1
Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.
University of Illinois
53
Metabolism-Guided Selective Androgen Receptor Antagonists: Design, Synthesis, and Biological Evaluation for Activity against Enzalutamide-Resistant Prostate Cancer.
University of Tennessee Health Science Center
19
Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer.
Shanghai Institute of Materia Medica
7
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
University of Michigan
1
PROTACS: A technology with a gold rush-like atmosphere.
China Pharmaceutical University
25
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators.
Pharmaceutical Research Institute
3
Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethyl-benzimidazole scaffold.
Johnson & Johnson Pharmaceutical Research and Development
2
Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist.
Orebro University
3
Total synthesis, chemical modification and structure-activity relationship of bufadienolides.
Nanjing University of Chinese Medicine
17
Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo[1,5-
Prince Sattam Bin Abdulaziz University
6
A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives.
China Pharmaceutical University
1
Anticancer potential of spirocompounds in medicinal chemistry: A pentennial expedition.
National Institute of Pharmaceutical Education and Research (NIPER)
78
Identification of the gossypol derivatives as androgen receptor inhibitor.
Zhejiang Normal University
17
Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.
Tianjin University
19
Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.
Mcgill University
24
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
Mitsubishi Tanabe Pharma
10
Ligands with dual vitamin D3-agonistic and androgen-antagonistic activities.
The University of Tokyo
38
Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).
China Pharmaceutical University
14
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
Shanghai Institute of Materia Medica
34
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
National Institute of Pharmaceutical Education and Research (NIPER)
15
Chemistry, biosynthesis and biological activity of terpenoids and meroterpenoids in bacteria and fungi isolated from different marine habitats.
Iranian Fisheries Science Research Institute
19
Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.
Bristol Myers Squibb
14
Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.
Bristol Myers Squibb
50
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
Zhejiang University
18
The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists.
Bristol Myers Squibb
10
Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.
University of Colorado
43
Discovery of novel nonsteroidal glucocorticoid receptor modulators.
Abbott Laboratories
22
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
Janssen Research and Development
18
Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.
Bristol Myers Squibb
15
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
Janssen Research and Development
3
Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer.
Bc Cancer
28
5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
Ligand Pharmaceuticals
25
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
University of Tennessee Health Science Center
5
Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor.
The University of Tokyo
33
Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonists.
Wyeth Research
36
Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines.
Abbott Laboratories
12
Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.
Usona Institute
5
A critical update on the strategies towards modulators targeting androgen receptors.
China Pharmaceutical University
18
Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD).
Mitobridge
6
New drug approvals for 2019: Synthesis and clinical applications.
Zhengzhou University
30
Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
Shanghai Institute of Materia Medica
2
Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
China Pharmaceutical University
10
Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
Zhejiang University
35
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
University of Nebraska Medical Center
50
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
University of Tennessee Health Science Center
19
Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
China Pharmaceutical University
1
Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
Zhejiang Normal University
13
Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity.
Abbott Laboratories
30
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Gifu Pharmaceutical University
3
Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands.
The University of Tennessee Health Science Center
10
Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
University of Maryland
26
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
School of Pharmacy and Pharmaceutical Sciences
35
Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer.
University of Pittsburgh
33
Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.
Ligand Pharmaceuticals
42
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
University of Tennessee Health Science Center
21
Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).
Oric Pharmaceuticals
26
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Genomics Institute of The Novartis Research Foundation (Gnf)
14
Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
Luoyang Normal University
23
Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.
Ligand Pharmaceuticals
20
Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one.
Ligand Pharmaceuticals
87
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
Bristol Myers Squibb
6
A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
Cardiff University
31
Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.
Rti International
28
New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.
Ligand Pharmaceuticals
1
Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
The Czech Academy of Sciences
24
5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
Ligand Pharmaceuticals
4
Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
Sichuan University and Collaborative Innovation Center For Biotherapy
24
5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
Ligand Pharmaceuticals
6
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Southern Medical University
2
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Eli Lilly
46
Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
University of British Columbia
70
Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain.
Csc-Scientific Computing
7
Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
Vancouver Prostate Centre (Vpc)
32
5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
Kanazawa University
18
Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-β agonists (SERBAs).
Marquette University
10
Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.
National Institute of Health Sciences
38
Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile.
AstraZeneca
26
Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Ochanomizu University
28
Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).
Oric Pharmaceuticals
34
Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.
The University of Tokyo
1
High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
Nanjing Forestry University
3
Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
China Pharmaceutical University
4
Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
China Pharmaceutical University
26
Structure-Based Approach To Identify 5-[4-Hydroxyphenyl]pyrrole-2-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators.
Pfizer
30
Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.
AstraZeneca
15
Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.
Pfizer
1
Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles.
Chinese Academy of Sciences
20
Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.
Takeda Pharmaceutical
10
Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer.
Drexel University College of Medicine
316
HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF
Tenaya Therapeutics
47
TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
The State University of New York
174
PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
Broadenbio
17
Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof
Chia Tai Tianqing Pharmaceutical Group
246
Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
Janssen Pharmaceutica
16
Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
Achillion Pharmaceuticals
20
Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors
Recordati Ireland
53
Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
Effector Therapeutics
2
Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
Beijing Konruns Pharmaceutical
6
Heterocyclic pyrazole compounds, method for preparing the same and use thereof
Development Center For Biotechnology
9
Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194).
Ucb Pharma
4
A robust GTP-induced shift in alpha(2)-adrenoceptor agonist affinity in tissue sections from rat brain.
University of Nebraska
19
Pharmacological comparison between [3H]GR 113808 binding sites and functional 5-HT4 receptors in neurons.
Cnrs Upr 9023
3
Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
Merck Sharp and Dohme Research Laboratories
11
The pharmacological profile of cloned and stably expressed alpha 1b-adrenoceptor in CHO cells.
National Children'S Medical Research Center
20
Inhibition studies of porphobilinogen synthase from Escherichia coli differentiating between the two recognition sites.
University of NeuchÂTel
4
Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717.
Lawrence Berkeley National Laboratory
45
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.
Pharmacia Italia
29
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
Nerviano Medical Sciences
22
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
Dupont Pharmaceuticals